心不全治療薬の世界市場レポート 2025年

心不全治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.2%で143億7,000万米ドルに成長します。予測期間中の成長は、個別化医療・精密医療の拡大、生活習慣病の世界の負担増、併用療法や合剤製剤の充実したパイプライン、臨床エビデンスの増加やガイドラインの更新、都市化の進展などの要因によるものと考えられます。予測期間における主な動向としては、SGLT2阻害薬の成長、デジタルヘルス技術の統合、遠隔モニタリングツールやAI主導型分析の活用、HFpEF治療への重点化、研究開発の継続などが挙げられます。

心血管疾患の有病率の増加は、今後数年間における心不全治療薬市場の拡大を促進すると予想されます。心血管疾患には心臓や血管に影響を及ぼす疾患が含まれ、しばしば心臓発作や脳卒中などの深刻な問題につながります。このような心血管疾患の増加は、主に心臓や血管の健康を徐々に損なう座りがちな生活習慣によるものです。このような疾患の発生率が増加するにつれて、効果的な治療に対する需要も高まり、心不全治療薬への投資が活発化しています。心不全が一般的になるにつれ、製薬会社は症状をよりよく管理し、患者の予後を改善するための治療法の開発・改良に力を注いでいます。例えば、2024年9月に米国心不全学会（HFSA）が報告したところによると、20歳以上の米国人で心不全（HF）を患っている患者は約670万人で、この数は2030年までに870万人、2040年までに1,030万人、2050年までに1,140万人に増加すると予想されています。このように、心血管疾患の罹患率の上昇は、心不全治療薬市場の成長の主要な促進要因となっています。

心不全治療薬市場の主要企業は、Na-グルコース共輸送体（SGLT）阻害薬など、心不全の症状や合併症をより効果的に長期管理できる先進薬の開発に注力しています。SGLT阻害薬は、グルコースの再吸収機構を標的とする先進的な薬剤で、心不全の管理、治療効率の向上、心血管の健康の最適化に役立ちます。例えば、2023年5月、米国のバイオ医薬品会社Lexicon Pharmaceuticalsは、FDA（米国食品医薬品局）の承認を取得した薬剤、Inpefa（ソタグリフロジン）を発売しました。Inpefaは1日1回投与の経口錠剤で、心不全や2型糖尿病、慢性腎臓病、その他の心血管危険因子を有する成人における心血管死、心不全による入院、心不全による緊急受診のリスクを低減するよう設計されています。今回の承認はLexiconの大きな成果であり、Inpefaは上市される初めてのSGLT1/SGLT2デュアル阻害剤であり、様々な病態を有する心不全患者に新たな治療選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場 - 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の心不全治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の心不全治療薬市場：成長率分析
• 世界の心不全治療薬市場の実績：規模と成長, 2019-2024
• 世界の心不全治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の心不全治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の心不全治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンジオテンシン変換酵素（ACE）阻害薬
• ベータ遮断薬
• 利尿薬
• アルドステロン拮抗薬
• アンジオテンシンII受容体拮抗薬（ARB）
• その他
• 世界の心不全治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 静脈内
• その他
• 世界の心不全治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他
• 世界の心不全治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• その他
• 世界の心不全治療薬市場：アンジオテンシン変換酵素（ACE）阻害薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エナラプリル
• リシノプリル
• ラミプリル
• カプトプリル
• ペリンドプリル
• その他
• 世界の心不全治療薬市場：ベータ遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルベジロール
• メトプロロールコハク酸塩
• ビソプロロール
• ネビボロール
• その他
• 世界の心不全治療薬市場：利尿薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ループ利尿薬
• チアジド系利尿薬
• カリウム保持性利尿薬
• その他
• 世界の心不全治療薬市場：アルドステロン拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• スピロノラクトン
• エプレレノン
• その他
• 世界の心不全治療薬市場：アンジオテンシンII受容体拮抗薬（ARB）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バルサルタン
• ロサルタン
• カンデサルタン
• イルベサルタン
• その他
• 世界の心不全治療薬市場：その他の薬剤クラスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンジオテンシン受容体ネプリライシン阻害薬
• イバブラジン
• ナトリウム-グルコース共輸送体-2（SGLT2）阻害薬
• ヒドララジン/硝酸イソソルビド
• ジゴキシン
• その他

第7章 地域別・国別分析

• 世界の心不全治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の心不全治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 心不全治療薬市場：競合情勢
• 心不全治療薬市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Boehringer Ingelheim Pharmaceuticals Inc.
• Steris Pharma
• CSPC Pharmaceutical
• Hikma Pharmaceuticals PLC
• Cadila Pharmaceuticals
• Ionis Pharmaceuticals Inc.
• Valeant Pharmaceuticals International Inc.
• Hainan Poly Pharm. Co. Ltd.
• Addii Biotech
• Lunan Pharmaceutical Group
• Mylan Laboratories Inc.
• Neuracle Lifesciences Private Limited
• JM Laboratories

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 心不全治療薬市場2029：新たな機会を提供する国
• 心不全治療薬市場2029：新たな機会を提供するセグメント
• 心不全治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Medications for heart failure are drugs designed to treat and manage heart failure, a condition in which the heart struggles to pump blood effectively to meet the body's needs. These medications help improve heart function, alleviate symptoms, prevent hospitalizations, and enhance survival.

The main drug classes used to treat heart failure include angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, aldosterone antagonists, angiotensin II receptor blockers (ARBs), and others. ACE inhibitors work by relaxing blood vessels through the inhibition of angiotensin II formation, which helps lower blood pressure and reduce the heart's workload. They are commonly prescribed for both high blood pressure and heart failure. These medications are administered via different routes, such as oral and intravenous, and are distributed through various channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others. They are used in a range of settings, including hospitals, clinics, and more.

The medications for heart failure market research report is one of a series of new reports from The Business Research Company that provides medications for heart failure market statistics, including the medications for heart failure industry global market size, regional shares, competitors with the medications for heart failure market share, detailed medications for heart failure market segments, market trends, and opportunities, and any further data you may need to thrive in the medications for heart failure industry. This medications for heart failure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The medications for the heart failure market size has grown strongly in recent years. It will grow from$10.14 billion in 2024 to $10.90 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth during the historic period can be attributed to factors such as the rising prevalence of cardiovascular diseases, increased diagnosis and awareness, regulatory approvals and support, higher R&D spending on cardiovascular drugs, and the adoption of telemedicine and remote monitoring tools.

The medications for the heart failure market size is expected to see strong growth in the next few years. It will grow to$14.37 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth during the forecast period can be attributed to factors such as the expansion of personalized and precision medicine, the rising global burden of lifestyle diseases, a robust pipeline of combination therapies and fixed-dose formulations, increasing clinical evidence and updated guidelines, and growing urbanization. Key trends in the forecast period include the growth of SGLT2 inhibitors, integration of digital health technologies, the use of remote monitoring tools and AI-driven analytics, a greater focus on HFpEF treatment, and ongoing research and development efforts.

The growing prevalence of cardiovascular diseases is expected to drive the expansion of the heart failure medications market in the coming years. Cardiovascular diseases encompass conditions affecting the heart and blood vessels, often leading to serious problems such as heart attacks and strokes. This rise in cardiovascular diseases is primarily due to sedentary lifestyles, which progressively impair heart and vessel health. As the incidence of these diseases increases, the demand for effective treatments also grows, prompting more investment in heart failure medications. With the condition becoming more common, pharmaceutical companies are focusing on developing and improving therapies to better manage symptoms and enhance patient outcomes. For example, in September 2024, the Heart Failure Society of America (HFSA) reported that approximately 6.7 million Americans aged 20 and older are living with heart failure (HF), a number expected to grow to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Thus, the rising incidence of cardiovascular diseases is a key driver of the heart failure medications market's growth.

Leading companies in the heart failure medication market are focused on developing advanced drugs such as sodium-glucose cotransporter (SGLT) inhibitors, which offer more effective long-term management of heart failure symptoms and complications. An SGLT inhibitor is an advanced drug that targets glucose reabsorption mechanisms, helping to manage heart failure, enhance treatment efficiency, and optimize cardiovascular health. For example, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, launched Inpefa (sotagliflozin), a medication approved by the Food and Drug Administration (FDA). Inpefa is a once-daily oral tablet designed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval represents a significant achievement for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to be marketed, offering a new treatment option for heart failure patients with various conditions.

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for $1.112 billion. The acquisition aims to strengthen Novo Nordisk's cardiovascular drug pipeline, particularly with Cardior's lead compound CDR132L, which is currently in phase 2 clinical trials for treating heart failure. Cardior Pharmaceuticals, based in Germany, specializes in researching oligonucleotide-based inhibitors for heart failure treatment.

Major players in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, and Lexicon Pharmaceuticals.

North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in medications for the heart failure report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the medications for the heart failure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The medications for the heart failure market consist of sales of angiotensin receptor-neprilysin inhibitors, hydralazine and nitrates, ivabradine, and digoxin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Medications For Heart Failure Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on medications for heart failure market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for medications for heart failure ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The medications for heart failure market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Beta Blockers; Diuretics; Aldosterone Antagonists; Angiotensin II Receptor Blockers (ARBs); Other Drug Classes
• 2) By Route Of Administration: Oral; Intravenous; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By Application: Hospital; Clinic; Other Applications
• Subsegments:
• 1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril; Lisinopril; Ramipril; Captopril; Perindopril; Other Angiotensin-Converting Enzyme (ACE) Inhibitors
• 2) By Beta Blockers: Carvedilol; Metoprolol Succinate; Bisoprolol; Nebivolol; Other Beta Blockers
• 3) By Diuretics: Loop Diuretics; Thiazide Diuretics; Potassium-Sparing Diuretics; Other Diuretics
• 4) By Aldosterone Antagonists: Spironolactone; Eplerenone; Other Aldosterone Antagonists
• 5) By Angiotensin II Receptor Blockers (ARBs): Valsartan; Losartan; Candesartan; Irbesartan; Other Angiotensin II Receptor Blockers (ARBs)
• 6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors; Ivabradine; Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors; Hydralazine Or Isosorbide Dinitrate; Digoxin; Other Medications
• Companies Mentioned: Merck & Co. Inc.; Bayer AG; Sanofi SA; Bristol-Myers Squibb; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Medications For Heart Failure Market Characteristics

3. Medications For Heart Failure Market Trends And Strategies

4. Medications For Heart Failure Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Medications For Heart Failure Growth Analysis And Strategic Analysis Framework

• 5.1. Global Medications For Heart Failure PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Medications For Heart Failure Market Growth Rate Analysis
• 5.4. Global Medications For Heart Failure Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Medications For Heart Failure Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Medications For Heart Failure Total Addressable Market (TAM)

6. Medications For Heart Failure Market Segmentation

• 6.1. Global Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Angiotensin II Receptor Blockers (Arbs)
• Other Drug Classes
• 6.2. Global Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Other Routes Of Administration
• 6.3. Global Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Medications For Heart Failure Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• Other Applications
• 6.5. Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enalapril
• Lisinopril
• Ramipril
• Captopril
• Perindopril
• Other Angiotensin-Converting Enzyme (ACE) Inhibitors
• 6.6. Global Medications For Heart Failure Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Carvedilol
• Metoprolol Succinate
• Bisoprolol
• Nebivolol
• Other Beta Blockers
• 6.7. Global Medications For Heart Failure Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Loop Diuretics
• Thiazide Diuretics
• Potassium-Sparing Diuretics
• Other Diuretics
• 6.8. Global Medications For Heart Failure Market, Sub-Segmentation Of Aldosterone Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spironolactone
• Eplerenone
• Other Aldosterone Antagonists
• 6.9. Global Medications For Heart Failure Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Valsartan
• Losartan
• Candesartan
• Irbesartan
• Other Angiotensin II Receptor Blockers (ARBs)
• 6.10. Global Medications For Heart Failure Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin Receptor-Neprilysin Inhibitors
• Ivabradine
• Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
• Hydralazine Or Isosorbide Dinitrate
• Digoxin
• Other Medications

7. Medications For Heart Failure Market Regional And Country Analysis

• 7.1. Global Medications For Heart Failure Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Medications For Heart Failure Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Medications For Heart Failure Market

• 8.1. Asia-Pacific Medications For Heart Failure Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Medications For Heart Failure Market

• 9.1. China Medications For Heart Failure Market Overview
• 9.2. China Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Medications For Heart Failure Market

• 10.1. India Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Medications For Heart Failure Market

• 11.1. Japan Medications For Heart Failure Market Overview
• 11.2. Japan Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Medications For Heart Failure Market

• 12.1. Australia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Medications For Heart Failure Market

• 13.1. Indonesia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Medications For Heart Failure Market

• 14.1. South Korea Medications For Heart Failure Market Overview
• 14.2. South Korea Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Medications For Heart Failure Market

• 15.1. Western Europe Medications For Heart Failure Market Overview
• 15.2. Western Europe Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Medications For Heart Failure Market

• 16.1. UK Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Medications For Heart Failure Market

• 17.1. Germany Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Medications For Heart Failure Market

• 18.1. France Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Medications For Heart Failure Market

• 19.1. Italy Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Medications For Heart Failure Market

• 20.1. Spain Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Medications For Heart Failure Market

• 21.1. Eastern Europe Medications For Heart Failure Market Overview
• 21.2. Eastern Europe Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Medications For Heart Failure Market

• 22.1. Russia Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Medications For Heart Failure Market

• 23.1. North America Medications For Heart Failure Market Overview
• 23.2. North America Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Medications For Heart Failure Market

• 24.1. USA Medications For Heart Failure Market Overview
• 24.2. USA Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Medications For Heart Failure Market

• 25.1. Canada Medications For Heart Failure Market Overview
• 25.2. Canada Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Medications For Heart Failure Market

• 26.1. South America Medications For Heart Failure Market Overview
• 26.2. South America Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Medications For Heart Failure Market

• 27.1. Brazil Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Medications For Heart Failure Market

• 28.1. Middle East Medications For Heart Failure Market Overview
• 28.2. Middle East Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Medications For Heart Failure Market

• 29.1. Africa Medications For Heart Failure Market Overview
• 29.2. Africa Medications For Heart Failure Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Medications For Heart Failure Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Medications For Heart Failure Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Medications For Heart Failure Market Competitive Landscape And Company Profiles

• 30.1. Medications For Heart Failure Market Competitive Landscape
• 30.2. Medications For Heart Failure Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Medications For Heart Failure Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Boehringer Ingelheim Pharmaceuticals Inc.
• 31.4. Steris Pharma
• 31.5. CSPC Pharmaceutical
• 31.6. Hikma Pharmaceuticals PLC
• 31.7. Cadila Pharmaceuticals
• 31.8. Ionis Pharmaceuticals Inc.
• 31.9. Valeant Pharmaceuticals International Inc.
• 31.10. Hainan Poly Pharm. Co. Ltd.
• 31.11. Addii Biotech
• 31.12. Lunan Pharmaceutical Group
• 31.13. Mylan Laboratories Inc.
• 31.14. Neuracle Lifesciences Private Limited
• 31.15. JM Laboratories

32. Global Medications For Heart Failure Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Medications For Heart Failure Market

34. Recent Developments In The Medications For Heart Failure Market

35. Medications For Heart Failure Market High Potential Countries, Segments and Strategies

• 35.1 Medications For Heart Failure Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Medications For Heart Failure Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Medications For Heart Failure Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer